25 LLC’s United Therapeutics UTHR Stock Holding History

25 LLC’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-4	Closed	-$920	–	540
2023 Q2	$920	Buy	+4	New	+$886	﹤0.01%	304

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

25 LLC's UTHR Position: Q3 2023 in Review

25 LLC sold out of United Therapeutics (UTHR) in Q3 2023, closing a stake of 4 shares — an estimated $920 sold.

25 LLC first reported a position in UTHR in Q2 2023 and held it in 1 quarter. The position peaked at $920 in Q2 2023. 508 funds tracked by Wall St. Rank hold UTHR as of Q3 2023.

25 LLC reported no remaining United Therapeutics position as of Q3 2023 after selling out during the quarter.
25 LLC sold 4 United Therapeutics shares in Q3 2023, an estimated $920.
25 LLC first reported a position in United Therapeutics in Q2 2023 and held it in 1 quarter.
25 LLC's United Therapeutics position peaked at $920 in Q2 2023.
508 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2023.

Based on 25 LLC's 13F filing for Q3 2023, filed 18 Oct 2023.